CSF Biomarkers in Prediction of Cerebral and Clinical Change in Mild Cognitive Impairment and Alzheimer's Disease

• DOI: 10.1523/jneurosci.3785-09.2010
• Publication Date: 2010-02-10T17:33:24Z
• Authors: Anders M. Fjell; Kristine B. Walhovd; Christine Fennema...; Linda K. McEvoy; Donald J. Hagler; Dominic Holland; James B. Brewer; Anders M. Dale
• Keywords: Clinical Dementia Rating; Cognitive Decline; Brain morphometry

Brain atrophy and altered CSF levels of amyloid β (Aβ 42 ) the microtubule-associated protein tau are potent biomarkers Alzheimer's disease (AD)-related pathology. However, relationship between brain morphometry is poorly understood. Thus, we addressed following questions. (1) Can biomarker explain morphometric differences normal controls (NC) patients with mild cognitive impairment (MCI) or AD? (2) How related to across brain? (3) closely clinical change [clinical dementia rating sum boxes (CDR-sb)]? Three hundred seventy participants (105 NC, 175 MCI, 90 AD) from Disease Neuroimaging Initiative were studied, whom 309 followed for 1 year 176 2 years. Analyses performed entire cortical surface, as well 30 subcortical regions interest. Results showed that could not account group in at baseline but moderate relationships longitudinal rates numerous areas, restricted medial temporal structures. Baseline was least predictive biomarkers. Even MCI Aβ comparable p-tau lower than more controls. Morphometry predicted CDR-sb better did These results indicate changes AD secondary two types yield complementary information.